Citius Pharmaceuticals Reports Topline Data from the Pivotal Phase 3 Study of Cancer Immunotherapy.
Citius Pharmaceuticals Reports Topline Data from the Pivotal Phase 3 Study of Cancer Immunotherapy I/ONTAK (E7777) for the Treatment of Persistent or...
Citius Pharma (CTXR) Flexes Muscle in Business Update. Remains Our Top Idea.
Added to Watch List November 2019 @$0.55.
Named Our Top Idea in 2020 @$1.02.Remains Our Top Idea in 2021...
Hapbee (HAPB) Expands Leadership Team to Support Aggressive Growth Strategy
VANCOUVER, BC, Aug. 6, 2021 /CNW/ - Hapbee Technologies, Inc. (TSXV: HAPB) (OTCQB: HAPBF) (FSE: HA1) ("Hapbee" or the "Company"), the leading wearable, wellness technology company has...
Citius Pharma (CTXR) $2.15. Price Target of $8.00 Maintained, Post Safety and Efficacy Review.
Investment Banker Buy Rating Maintained: DSMB Gives the Thumbs Up – Data in Early 2022.
CITIUS NEWS ARCHIVE
Preventing Type I Diabetes. Here’s How Provention (PRVB) Works.
Here's How Provention's Treatment Works.
Interview With an Actual Provention Bio (PRVB) Clinical Trial Participant.
Citius (CTXR). Dang Flippers!
Short term investors powered Citius from $2.50 to near $4.50 in hopes of a positive early trial...
Teplizumab: Can We Delay the Onset of Type 1? (DiaTribe)
Teplizumab: Can We Delay the Onset of Type 1?
Last updated: 6/7/21
By Dr. Francine...
Citius (CTXR) Expands Scientific Advisory Board. Dr. John Laffey, Expert in Stem Cell and...
- Addition of leading scholar and KOL in acute respiratory distress syndrome (ARDS) to ARDS Scientific Advisory Board supports continued progress of...
More Great News From Citius Pharma (CTXR).
UPDATED CHART 6-15-21
Mino-Lok® Phase III, FDA NewsRussell 2000 Index NewsTechnical Breakout News
Stocks On The Move!
Citius (CTXR) up 19%, Draganfly (DFLYF) up 31%, urban-gro (UGRO) up 37%, Provention (PVRB) flip-flopping, Hapbee Technologies (HAPBF) up 26% and the...